{"id":"a1cb92c6-aefb-4cee-b4ae-d2749553b4a8","kind":"news","code":"a1cb92c6-aefb-4cee-b4ae-d2749553b4a8","name":"iRegene raises RMB 100 million in Series B financing","nameBasis":"translated-title","summary":"","description":"","country":null,"category":null,"originalName":"睿健医药完成1亿元B轮融资","eventDate":"2025-09-04T00:00:00.000Z","website":null,"sourceUpdatedAt":"2026-10-10T18:48:19.834Z","englishUpdatedAt":"2026-10-15T17:19:59.807Z","reviewedAt":"2026-10-15T17:19:59.807Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"f53b92a2dfa97b78ead9f1687d7dff7d4a48c4b8c9f6be719aaa522f5ffcdce5","companyId":"c6f40f74-5248-4720-8404-fd1e03022e90","foundedYear":null,"logoUrl":null,"originalText":"","sources":[],"related":[{"id":"46912db4-929a-452f-85e6-bf2574fde0d5","kind":"institutions","code":"UB-I185","name":"Beijiguang Venture Capital","nameBasis":"transliterated","summary":"A well-known Chinese venture capital firm focused on early-stage technology and healthcare investments.","description":"A well-known Chinese venture capital firm focused on early-stage technology and healthcare investments.","country":null,"category":null,"originalName":"北极光创投","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T10:54:25.119Z","englishUpdatedAt":"2026-10-15T21:21:01.645Z","reviewedAt":"2026-10-15T21:21:01.645Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"a8028420b266fdcda07a3c9671ee7ce3af8078ac855a0d85bbed40f24b8d52c1","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/institutions/beijiguang-venture-capital"},{"id":"781c29b1-c5f1-4341-808a-6b1f73582d58","kind":"institutions","code":"UB-I2378","name":"Chuangjing Capital","nameBasis":"transliterated","summary":"Chuangjing Capital is a mainland Chinese venture capital firm, focused on early-stage innovation projects.","description":"Chuangjing Capital is a mainland Chinese venture capital firm, focused on early-stage innovation projects.","country":null,"category":null,"originalName":"创景资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:36:31.031Z","englishUpdatedAt":"2026-10-15T18:43:03.680Z","reviewedAt":"2026-10-15T18:43:03.680Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"65a754d3fe5e3ef09a6e193b029044a4335a9fc03e7da2f8d932b279dd280edc","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/institutions/chuangjing-capital"},{"id":"9b42b473-f161-424b-8466-d5fa40287648","kind":"institutions","code":"UB-I1805","name":"Jinshajianglianhe Capital","nameBasis":"transliterated","summary":"A CNY-denominated venture capital firm that is a separate entity from GSR Ventures.","description":"A CNY-denominated venture capital firm that is a separate entity from GSR Ventures.","country":null,"category":null,"originalName":"金沙江联合资本","eventDate":null,"website":null,"sourceUpdatedAt":"2026-10-15T11:04:24.137Z","englishUpdatedAt":"2026-10-15T21:21:01.731Z","reviewedAt":"2026-10-15T21:21:01.731Z","snapshotAt":"2026-10-15T14:23:27.067Z","sourceHash":"8aed6e70f5776c234d28e5d2782262b4f3333b5a68069563063f3deb13f0bff1","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/institutions/jinshajianglianhe-capital"},{"id":"c6f40f74-5248-4720-8404-fd1e03022e90","kind":"companies","code":"UB-C5987","name":"iRegene","nameBasis":"source-english","summary":"AI and chemically induced cell drug research and development.","description":"","country":"China","category":null,"originalName":"睿健医药","eventDate":null,"website":"https://www.iregene.com/","sourceUpdatedAt":"2026-10-08T00:00:00.000Z","englishUpdatedAt":"2026-10-20T18:26:36.154Z","reviewedAt":"2026-10-20T18:26:36.154Z","snapshotAt":"2026-10-20T18:05:01.520Z","sourceHash":"4f1558709e5410f70940856de858bdad558b4dea9749771117809729b847f483","companyId":null,"foundedYear":null,"logoUrl":null,"path":"/companies/UB-C5987"}],"path":"/news/a1cb92c6-aefb-4cee-b4ae-d2749553b4a8","structured":{"city":null,"country":null,"location":null,"role":null,"category":null,"company":{"name":"iRegene","path":"/companies/UB-C5987"}},"canonical":"https://uniquebase.ai/news/a1cb92c6-aefb-4cee-b4ae-d2749553b4a8"}